<?xml version="1.0"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
<channel>
<title>BloggingStocks</title>
<link>http://www.bloggingstocks.com</link>
<description>BloggingStocks</description>
<image>
<url>http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif</url>
<title>BloggingStocks</title>
<link>http://www.bloggingstocks.com</link>
</image>
<language>en-us</language>
<copyright>Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only.</copyright>
<generator>Blogsmith http://www.blogsmith.com/</generator><item><title><![CDATA[Options Update: Wyeth volatility at 46 into report Pfizer in talks to acquire WYE]]></title><link>http://www.bloggingstocks.com/2009/01/23/options-update-wyeth-volatility-at-46-into-report-pfizer-in-tal/</link><guid isPermaLink="true">http://www.bloggingstocks.com/2009/01/23/options-update-wyeth-volatility-at-46-into-report-pfizer-in-tal/</guid><comments>http://www.bloggingstocks.com/2009/01/23/options-update-wyeth-volatility-at-46-into-report-pfizer-in-tal/#comments</comments><description><![CDATA[<p>Filed under: <a href="http://www.bloggingstocks.com/category/pfe/" rel="tag">Pfizer (PFE)</a>, <a href="http://www.bloggingstocks.com/category/options/" rel="tag">Options</a></p><p><strong><a href="http://finance.aol.com/quotes/wyeth/wye/nys/option-chains"><img alt="" src="http://www.blogcdn.com/www.bloggingstocks.com/media/2009/01/flywall_final_logo_mini.gif" align="right" />Wyeth</a></strong> (NYSE: <a href="http://finance.aol.com/quotes/wyeth/wye/nys/option-chains">WYE</a>) is recently trading at $42.06, above its close of $38.83. <a href="http://finance.aol.com/quotes/pfizer-inc/pfe/nys/option-chains">Pfizer</a> (NYSE-<a href="http://finance.aol.com/quotes/pfizer-inc/pfe/nys/option-chains">PFE</a>) is in talks to acquire WYE in a deal valued at $60B, reported the WSJ. WYE is expected to report Q4 EPS on January 29. WYE February and March option implied volatility of 46 is near its 26-week average of 43, according to Track Data, suggesting non-directional price movement.</p>
<p>PFE is recently trading at $16.77, below its close of $17.21. PFE is expected to report Q4 EPS on January 28. PFE February volatility of 37 is near its 26-week average according to Track Data, suggesting non-directional price movement. </p>
<p><strong><a href="http://finance.aol.com/quotes/crucell-nv-american-depositary-shares/crxl/nas/option-chains">Crucell NV</a></strong> (NASDAQ: <a href="http://finance.aol.com/quotes/crucell-nv-american-depositary-shares/crxl/nas/option-chains">CRXL</a>), a biopharmaceutical company, and WYE confirmed on January 7 the two firms are in discussion to combine. CRXL closed at $22.39 and was recently trading this morning at $19.91. CRXL February option implied volatility of 70 is above its 26 week average of 63, according to Track Data, suggesting larger price movement. </p>
<p><em>Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com</em>.</p><p style="padding:5px;background:#ddd;border:1px solid #ccc;clear:both;"><a href="http://www.bloggingstocks.com/2009/01/23/options-update-wyeth-volatility-at-46-into-report-pfizer-in-tal/">Options Update: Wyeth volatility at 46 into report Pfizer in talks to acquire WYE</a> originally appeared on <a href="http://www.bloggingstocks.com">BloggingStocks</a> on Fri, 23 Jan 2009 10:30:00 EST.  Please see our <a href="http://www.weblogsinc.com/feed-terms/">terms for use of feeds</a>.</p><h6 style="clear: both; padding: 8px 0 0 0; height: 2px; font-size: 1px; border: 0; margin: 0; padding: 0;"></h6><a href="http://www.bloggingstocks.com/2009/01/23/options-update-wyeth-volatility-at-46-into-report-pfizer-in-tal/" rel="bookmark" title="Permanent link to this entry">Permalink</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/forward/1438544/" title="Send this entry to a friend via email">Email this</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/2009/01/23/options-update-wyeth-volatility-at-46-into-report-pfizer-in-tal/#comments" title="View reader comments on this entry">Comments</a>]]></description><category>Crucell NV</category><category>CrucellNv</category><category>option implied volatility</category><category>OptionImpliedVolatility</category><category>Pfizer</category><category>Wyeth</category><dc:creator><![CDATA[Paul Foster]]></dc:creator><pubDate>Fri, 23 Jan 2009 10:30:00 EST</pubDate></item><item><title><![CDATA[Options Update: Elan (ELN) volatility up into strategic review]]></title><link>http://www.bloggingstocks.com/2009/01/13/options-update-elan-eln-volatility-up-into-strategic-review/</link><guid isPermaLink="true">http://www.bloggingstocks.com/2009/01/13/options-update-elan-eln-volatility-up-into-strategic-review/</guid><comments>http://www.bloggingstocks.com/2009/01/13/options-update-elan-eln-volatility-up-into-strategic-review/#comments</comments><description><![CDATA[<p>Filed under: <a href="http://www.bloggingstocks.com/category/options/" rel="tag">Options</a></p><p><a href="http://finance.aol.com/quotes/elan-corporation-plc/eln/nys/option-chains"><strong><img align="right" alt="" src="http://www.blogcdn.com/www.bloggingstocks.com/media/2009/01/flywall_final_logo_mini.gif" /></strong><strong>Elan</strong></a> (NYSE: <a href="http://finance.aol.com/quotes/elan-corporation-plc/eln/nys/option-chains">ELN</a>) said it is initiating a strategic review which could result in a minority investment, a strategic alliance, a merger, or a sale. ELN closed at $8.03 Monday. ELN February call option implied volatility is at 103, puts are at 112, above its 26-week average of 100 according to Track Data, suggesting larger price movement..</p>
<p><strong><a href="http://finance.aol.com/quotes/biogen-idec-incorporated/biib/nas/option-chains">Biogen Idec</a></strong> (NASDAQ: <a href="http://finance.aol.com/quotes/biogen-idec-incorporated/biib/nas/option-chains">BIIB</a>) closed at $48.45 Monday. BIIB and ELN have a 50-50 stake in the multiple sclerosis drug Tysabri. ELN said it is initiating a strategic review which could result in a minority investment, a strategic alliance, a merger or a sale. BIIB February option implied volatility of 56 is near its 26-week average according to Track Data, suggesting non-directional price movement. </p>
<p><strong><a href="http://finance.aol.com/quotes/crucell-nv-american-depositary-shares/crxl/nas/option-chains">Crucell NV</a></strong> (NASDAQ: <a href="http://finance.aol.com/quotes/crucell-nv-american-depositary-shares/crxl/nas/option-chains">CRXL</a>), a biopharmaceutical company, and <a href="http://finance.aol.com/quotes/wyeth/wye/nys/option-chains">Wyeth</a> (NYSE: <a href="http://finance.aol.com/quotes/wyeth/wye/nys/option-chains">WYE</a>) confirmed on January 7 the two firms are in discussion to combine. CRXL closed at $22.63 Monday. CRXL February option implied volatility of 58 is near its 26-week average of 61, according to Track Data, suggesting non-directional price movement.</p>
<p><em>Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com</em><br /></p><p style="padding:5px;background:#ddd;border:1px solid #ccc;clear:both;"><a href="http://www.bloggingstocks.com/2009/01/13/options-update-elan-eln-volatility-up-into-strategic-review/">Options Update: Elan (ELN) volatility up into strategic review</a> originally appeared on <a href="http://www.bloggingstocks.com">BloggingStocks</a> on Tue, 13 Jan 2009 08:38:00 EST.  Please see our <a href="http://www.weblogsinc.com/feed-terms/">terms for use of feeds</a>.</p><h6 style="clear: both; padding: 8px 0 0 0; height: 2px; font-size: 1px; border: 0; margin: 0; padding: 0;"></h6><a href="http://www.bloggingstocks.com/2009/01/13/options-update-elan-eln-volatility-up-into-strategic-review/" rel="bookmark" title="Permanent link to this entry">Permalink</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/forward/1428008/" title="Send this entry to a friend via email">Email this</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/2009/01/13/options-update-elan-eln-volatility-up-into-strategic-review/#comments" title="View reader comments on this entry">Comments</a>]]></description><category>biib</category><category>Biogen Idec</category><category>BiogenIdec</category><category>Crucell NV</category><category>CrucellNv</category><category>crxl</category><category>Elan</category><category>eln</category><category>multiple sclerosis drug Tysabri.</category><category>MultipleSclerosisDrugTysabri.</category><category>option implied volatility</category><category>OptionImpliedVolatility</category><category>wye</category><category>Wyeth</category><dc:creator><![CDATA[Paul Foster]]></dc:creator><pubDate>Tue, 13 Jan 2009 08:38:00 EST</pubDate></item></channel></rss>
